Healthcare — US PTAB Patent Cases
12 decisions indexed
Page 1 of 1 · 12 total
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB found all 20 claims of the '11634781 patent unpatentable as obvious under 35 U.S.C. § 103. The Board concluded that combining prior art references, specifically Lenhard, Vilkin, and Itzkowitz, taught or suggested every element of independent claim 1 with a reasonable expectation of success. This decision rejects the Patent Owner's arguments regarding lack of motivation to combine the cited art.
Mito Red Light, Inc. v.Joovv, Inc.
Mito Red Light, Inc.'s challenge against Joovv, Inc.'s light therapy patent was denied by the PTAB. The Board found that Petitioner failed to establish unpatentability under § 103 using references Dijkstra and Norwood.
Teladoc Health, Inc. v.Data Health Partners, Inc.
Teladoc Health's IPR petition against Data Health Partners was denied by the PTAB, failing to establish a reasonable likelihood of prevailing on any claim. The Board adopted the Patent Owner's narrow construction of 'without input from the clients,' reinforcing its exclusion of client-initiated data when generating scores.
Teladoc Health, Inc. v.Data Health Partners, Inc.
The PTAB issued a Final Written Decision finding that numerous claims of the patent were unpatentable based on obviousness. The Petitioner successfully demonstrated that various combinations of prior art references rendered the claimed features predictable to one skilled in the art.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. successfully petitioned to challenge DexCom's CGM patent (9119528) on grounds of anticipation and obviousness over Brauker. The Board found a reasonable likelihood of unpatentability for the challenged claims, leading to institution.
Geneoscopy, Inc. v.Exact Sciences Corporation
Geneoscopy, Inc. successfully petitioned the PTAB to institute an IPR against Exact Sciences Corporation's patent (11634781). The Board found a reasonable likelihood of prevailing on all grounds, specifically regarding obviousness under 35 U.S.C. § 103.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB instituted an IPR in a colorectal cancer screening case, finding a reasonable likelihood that Geneoscopy's challenged claims are unpatentable. The Board accepted the petitioner's argument that combinations of various prior art references teach every limitation of the claims with a reason for combination.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed Corp. successfully convinced the PTAB to institute IPR proceedings against Cleveland Medical Devices, Inc.'s patent (No. 11690512). The Board found that ResMed demonstrated a reasonable likelihood of prevailing on Ground 1, allowing the challenge to proceed despite neutral merits.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect Operating lost its IPR challenge against Align Technology's '879 patent in a PTAB decision focused on obviousness. The Board rejected the petitioner’s argument that combining prior art references would render the claims obvious, upholding the validity of the challenged technology in orthodontics.
Geneoscopy, Inc. v.Exact Sciences Corporation
Geneoscopy challenges Exact Sciences' '781 patent on grounds of obviousness (103) related to colorectal cancer diagnostics. The petitioner argues that combining known methods for fecal sample processing, such as DNA methylation and blood protein testing, renders the claims unpatentable over prior art references. This challenge targets multiple diagnostic claim sets across the patent.
Teladoc Health, Inc. v.Data Health Partners, Inc.
Teladoc Health, Inc. challenges the validity of Data Health Partners' patent (11144554) in an IPR proceeding, asserting that the goal-tracking system is obvious under 35 U.S.C. § 103. The petitioner relies on multiple combinations of prior art references, including Douglas, Wager, Chitiveli, Klotsche, and Koh, to invalidate numerous claims related to client/patient progress tracking in healthcare.
Teladoc Health, Inc. v.Data Health Partners, Inc.
Teladoc Health, Inc. challenged Data Health Partners, Inc.'s '812 Patent in an IPR proceeding, arguing the system for tracking client progress was obvious over various combinations of prior art. The PTAB determined that institution is appropriate, allowing the challenger to proceed with its grounds of obviousness (103).
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.